NEW YORK, April 23, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Landmark Bancorp Inc. (NASDAQ: LARK), Genetic Technologies Ltd (NASDAQ: GENE), Novogen Limited (NASDAQ: NVGN), CorMedix Inc. (NYSEMKT: CRMD), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
LARK Research Report: ( http://get.analystsreview.com/pdf/?c=Landmark%20Bancorp&d=23-Apr-2015&s=LARK ),
GENE Research Report: ( http://get.analystsreview.com/pdf/?c=Genetic%20Technologies&d=23-Apr-2015&s=GENE ),
NVGN Research Report: ( http://get.analystsreview.com/pdf/?c=Novogen%20Limited&d=23-Apr-2015&s=NVGN ),
CRMD Research Report: ( http://get.analystsreview.com/pdf/?c=CorMedix%20Inc.&d=23-Apr-2015&s=CRMD ),
BCRX Research Report: ( http://get.analystsreview.com/pdf/?c=BioCryst%20Pharmaceuticals&d=23-Apr-2015&s=BCRX ),
Analyst Update: Private Placement & Rights offering, Street Estimates and Strategic Initiatives
Reviewed by: Rohit Tuli, CFA®
U.S. stocks edged higher on Wednesday as better than expected earnings and strong existing home sales data bolstered investor sentiment. The NASDAQ advanced 0.42% to finish at 5,035.17, its third straight gain and just 13 points below its record close reached on March 10, 2000. The Dow Jones Industrial Average rose 0.49% or 88.35 points to 18,038.27, and the S&P 500 gained 0.50%, or 9.69 points to close the session at 2107.96. European stocks closed with a mixed note on Wednesday, depressed by increasing concern over Greece's bailout negotiations and disappointing earnings. Germany's DAX and Britain's FTSE 100 index slipped 0.6% and 0.5%, respectively, while France's CAC gained 0.36% on Wednesday. Meanwhile, Asian market continued their good run with The Shanghai Composite and Japan's Nikkei closing at new multi-year highs on Wednesday.
Landmark Bancorp, Inc. (Landmark) announced that it will release earnings for the first quarter of 2015 after the market closes on April 29, 2015, followed by a conference call to discuss these results on April 30, 2015 at 10:00 am (CT). Last quarter, the Company reported its fourth quarter net earnings of $2.1 million, a 300% jump from $0.52 million reported same period last year.
On April 20, 2015, Genetic Technologies Ltd announced that two new breast health centres will begin to offer BREVAGenplus® to their at-risk patients in a systematic fashion, which is in addition to the already operational six centers, that the Company previously announced were set to adopt the product. Of these, all six have provided samples during the March 2015 quarter, the Company informed.
On April 21, 2015, Novogen Limited (Novogen) released a press release stating that it has entered into definitive agreements to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of approximately AUD15.5 million.
On April 9, 2015, CorMedix Inc. announced a significant new program aimed at enhancing long term market competitiveness by substantially reducing the cost of goods of Neutrolin® Catheter Lock Solution through a more efficient, custom synthesis of the active ingredient taurolidine.
BioCryst Pharmaceuticals Inc. (BioCryst) would tentatively report its Q1 2015 results on May 8, 2015
According to estimates available from Yahoo Finance, BioCryst is expected to report revenues of $4.30 million and negative earnings of $0.25 this quarter.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review